These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17088172)

  • 21. Three potentially fatal adverse effects of psychotropic medications.
    Wren P; Frizzell LA; Keltner NL; Wright AV
    Perspect Psychiatr Care; 2003; 39(2):75-81. PubMed ID: 12894601
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal.
    Tanii H; Fujita K; Okazaki Y
    Am J Psychiatry; 2006 Mar; 163(3):547-8. PubMed ID: 16513884
    [No Abstract]   [Full Text] [Related]  

  • 23. [Symptom complex developing after the withdrawal of psychotropic drugs].
    Perényi A
    Orv Hetil; 1983 May; 124(18):1073-4. PubMed ID: 6866507
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of neuroleptic malignant syndrome during simultaneous amoxapine treatment and alprazolam discontinuation.
    Burch EA; Downs J
    J Clin Psychopharmacol; 1987 Feb; 7(1):55-6. PubMed ID: 3818996
    [No Abstract]   [Full Text] [Related]  

  • 25. A case of malignant syndrome associated with a parkinsonism patient.
    Sanga M; Nomura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuroleptic malignant syndrome. A case associated with amantadine withdrawal].
    Med Clin (Barc); 1985 Nov; 85(15):643-4. PubMed ID: 4079554
    [No Abstract]   [Full Text] [Related]  

  • 27. [Malignant Neuroleptic Syndrome during tiapride treatment].
    Tamion F; Petit J; Massari P; Leroy J; Biga N; Oksenhendler G
    J Toxicol Clin Exp; 1990; 10(7-8):461-7. PubMed ID: 2135061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An uncommon adverse effect of levodopa withdrawal in a patient taking antipsychotic medication: neuroleptic malignant-like syndrome.
    Man SP
    Hong Kong Med J; 2011 Feb; 17(1):74-6. PubMed ID: 21282831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative explanations for withdrawal psychosis.
    Cole JO; Lawrence J
    Am J Psychiatry; 1984 Sep; 141(9):1129-30. PubMed ID: 6465395
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuroleptic malignant syndrome following levomepromazine discontinuation.
    Tanii H; Saka K; Inoue K; Okada M
    J Neuropsychiatry Clin Neurosci; 2010; 22(2):E16. PubMed ID: 20463130
    [No Abstract]   [Full Text] [Related]  

  • 31. Antidepressant discontinuation syndrome.
    Warner CH; Bobo W; Warner C; Reid S; Rachal J
    Am Fam Physician; 2006 Aug; 74(3):449-56. PubMed ID: 16913164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications.
    Cosci F; Chouinard G
    Psychother Psychosom; 2020; 89(5):283-306. PubMed ID: 32259826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication.
    Stotz M; Thümmler D; Schürch M; Renggli JC; Urwyler A; Pargger H
    Br J Anaesth; 2004 Dec; 93(6):868-71. PubMed ID: 15377584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consequences of a benzodiazepine discontinuation programme in family practice on psychotropic medication prescription to the participants.
    Gorgels WJ; Oude Voshaar RC; Mol AJ; van de Lisdonk EH; Mulder J; van den Hoogen H; van Balkom AJ; Breteler MH; Zitman FG
    Fam Pract; 2007 Oct; 24(5):504-10. PubMed ID: 17644828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents.
    Spivak B; Gonen N; Mester R; Averbuch E; Adlersberg S; Weizman A
    Int Clin Psychopharmacol; 1996 Sep; 11(3):207-9. PubMed ID: 8923101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena.
    Bhanji NH; Chouinard G; Kolivakis T; Margolese HC
    Can J Clin Pharmacol; 2006; 13(1):e69-74. PubMed ID: 16456219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse reactions to sudden stoppage of drugs.
    Wahi S; Wahi PL
    J Assoc Physicians India; 1986 Mar; 34(3):205-6. PubMed ID: 2874126
    [No Abstract]   [Full Text] [Related]  

  • 38. Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!".
    Preskorn SH
    J Psychiatr Pract; 2007 Sep; 13(5):328-33. PubMed ID: 17890981
    [No Abstract]   [Full Text] [Related]  

  • 39. [A patient with Parkinson's disease complicated by hypothyroidism who developed malignant syndrome after discontinuation of etizolam].
    Kawajiri M; Ohyagi Y; Furuya H; Araki T; Inoue N; Esaki S; Yamada T; Kira J
    Rinsho Shinkeigaku; 2002 Feb; 42(2):136-9. PubMed ID: 12424963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychotropic drug-related eosinophilia with systemic symptoms after acute caffeine ingestion.
    Mahapatra S; Belgrad JL; Adeoye MA
    Pediatrics; 2011 Jan; 127(1):e235-8. PubMed ID: 21135003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.